source
- Are health insurers out of the woods after a tough 2025?Last year, health insurer after health insurer slashed or withdrew their profit outlooks after being sucker-punched by high medical costs. This year is shaping up ...Endpoints · 2mo ago↗ source
- Blackstone puts $250M into Anagram to tackle cystic fibrosis complicationBlackstone Life Sciences, fresh off one of the largest private investment funds in industry history, is putting $250 million to work on a little-known biotech seeking to drastically reduce the numb…Endpoints · 2mo ago↗ source
- Entrada stock falls on Duchenne data; Wegovy expands accessPlus, news about BioCryst, GSK and Roche. 🙃 Entrada’s Duchenne drug disappoints: The biotech reported initial data in six patients who received the low dose of its exon 44 skipping drug ...